NeuroPace, Inc.

NeuroPace, Inc. is a medical device company based in the United States that focuses on developing innovative treatments for drug-resistant focal epilepsy. Its primary product is the RNS System, a brain-responsive neuromodulation system that delivers personalized, real-time treatment directly at the seizure source. The system includes an RNS neurostimulator, cortical strip and depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories. Additionally, NeuroPace offers a physician tablet for programming implanted devices and managing patient care, as well as a patient data management system and the nSight Platform, which provides clinicians with personalized patient reports and programming suggestions.

NeuroPace, Inc. is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol NPCE. The company trades in United States Dollars (USD), which is the standard currency for stocks listed on U.S. exchanges. Investors can buy and sell shares of NeuroPace on the NasdaqGM during regular trading hours, and the stock price is quoted in USD.

NeuroPace operates in the Healthcare sector, specifically within the Medical Devices industry. As a medical device company, it focuses on developing and commercializing neuromodulation technologies for treating neurological disorders. Its primary product, the RNS System, is a brain-responsive neurostimulator designed to treat drug-resistant focal epilepsy by delivering real-time, personalized electrical stimulation at the seizure source.

NeuroPace, Inc. is headquartered in Mountain View, California, United States. The company was incorporated in 1997 and primarily serves the U.S. market, as indicated by its country and region designation. Its products are distributed to hospital facilities for initial RNS System implant procedures and for replacement procedures. While the company's focus is on the United States, its technology addresses a global need for treating drug-resistant focal epilepsy.

NeuroPace generates revenue primarily through the sale of its RNS System, which includes the RNS neurostimulator, cortical strip and depth leads, and associated accessories. The company distributes its products to hospital facilities for initial implant procedures and for replacement procedures when the neurostimulator's battery needs to be replaced. Additionally, NeuroPace offers the Patient Remote Monitor, physician tablet, and data management systems that support the ongoing use of the RNS System. These products and services are sold to healthcare providers, who then implant and manage the devices for patients with drug-resistant focal epilepsy.